Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06670911
Title	Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer. (ACCESS-I)
Acronym	ACCESS-I
Recruitment	Recruiting
Gender	female
Phase	Phase II
Variant Requirements	Yes
Sponsors	Instituto Nacional de Cancer, Brazil
Indications	cervical squamous cell carcinoma cervical adenocarcinoma cervical adenosquamous carcinoma
Therapies	Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Paclitaxel + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	BRA